Charles Schwab Investment Management Inc. lowered its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 16.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 349,730 shares of the biotechnology company's stock after selling 68,009 shares during the period. Charles Schwab Investment Management Inc. owned about 0.71% of REGENXBIO worth $2,703,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of the business. FMR LLC lifted its position in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,656 shares in the last quarter. GAMMA Investing LLC lifted its holdings in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 2,510 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of REGENXBIO during the 3rd quarter worth about $140,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of REGENXBIO by 8.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company's stock worth $1,273,000 after buying an additional 13,014 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of REGENXBIO in the third quarter valued at approximately $161,000. Hedge funds and other institutional investors own 88.08% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have commented on RGNX. HC Wainwright lowered their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. The Goldman Sachs Group cut REGENXBIO from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Morgan Stanley increased their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Leerink Partners set a $24.00 price target on REGENXBIO in a research note on Tuesday, March 18th. Finally, StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, REGENXBIO presently has an average rating of "Moderate Buy" and a consensus price target of $32.78.
Get Our Latest Research Report on REGENXBIO
REGENXBIO Price Performance
RGNX stock traded down $0.68 during midday trading on Monday, reaching $7.15. 1,049,957 shares of the company's stock traded hands, compared to its average volume of 767,079. REGENXBIO Inc. has a fifty-two week low of $5.62 and a fifty-two week high of $21.57. The business has a 50-day moving average price of $7.39 and a two-hundred day moving average price of $8.71. The company has a market capitalization of $358.11 million, a P/E ratio of -1.42 and a beta of 1.35.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. The company had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.
About REGENXBIO
(
Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
